DELRAY BEACH, Fla., Sept. 6, 2025 /PRNewswire/ -- The global Digital Health Market, valued at US$162.1 billion in 2024, stood…
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~…
Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's…
Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosingTxB2 is a biomarker…
NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL…
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)…
Guideline Emphasis on Earlier Treatment to Reduce Health, Dementia Risks Boosts Urgency to Keep Closer Watch on Blood Pressure OMRON…
According to the NIH, Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each…
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an…